Thymopentin and Antiretroviral Therapy in Asymptomatic HIV-Infected Patients

This study focuses on HIV-infected individuals who do not show any symptoms and are currently receiving either single or combination anti-retroviral therapy. The main goal is to validate the results from a previous study that found a slower disease progression when combining thymopentin with zidovudine (AZT), an antiretroviral drug. Additionally, the study aims to evaluate the effectiveness and safety of thymopentin in HIV-infected asymptomatic patients who are undergoing monotherapy with AZT, didanosine (ddI), or stavudine (d4T), or combination therapy with AZT/ddI or AZT/zalcitabine (ddC). This research is important as it could lead to improved treatment options and a better quality of life for individuals living with HIV. During the study, participants will continue their current anti-retroviral therapy while also receiving thymopentin. The effects of this combination will be carefully monitored to assess the safety and efficacy of thymopentin. The study will measure how well the treatment slows disease progression and manages HIV-related symptoms. It's important to note that like all clinical trials, this study comes with potential risks and benefits, which will be thoroughly explained to participants before they decide to take part.